NiKang Therapeutics Appoints Joanne Lager,M.D., as Chief Medical Officer
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
NiKang Therapeutics Enters Into Clinical Trial Collaboration and Supply Agreement to Evaluate NKT2152 in Combination with Standard-of-Care in First-Line Advanced Hepatocellular Carcinoma
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of Directors
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
NiKang Therapeutics Presents Preclinical Data Highlighting NKT2152’s Therapeutic Potential in Clear Cell Renal Cell Carcinoma (ccRCC) and Solid Tumors Beyond ccRCC at AACR Annual Meeting 2022
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!